Biointron
@Biointron2012
Followers
41
Following
115
Media
211
Statuses
851
Founded in 2012, we are a biotechnology CRO with expertise in antibody discovery. We have served biotech/biopharma companies worldwide.
New Jersey, US
Joined April 2023
🚀 Breakthrough in De Novo Antibody Design A new paper demonstrates, for the first time, the atomically accurate de novo design of antibodies using a fine-tuned RFdiffusion model. https://t.co/enzagBCdjL
https://t.co/enzagBCdjL
nature.com
Nature - The combination of computational design, laboratory-based screening and biophysical validation enables the de novo generation of variable heavy-chain antibody fragments and antibodies that...
0
0
0
💵 Apogee Therapeutics, Inc. announces closing of public offering of $345M, focuses on novel antibody programs. https://t.co/fGlVGTzWBQ
#Biointron #Antibodies #Immunotherapy #PharmaNews #Healthcare #DrugDevelopment #DrugDiscovery #Oncology #Innovation #Networking
investors.apogeetherapeutics.com
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for...
0
0
0
📈 @Nurix_Tx announces closing of $250M registered offering of common stock, funds to advance pipeline including degrader antibody conjugates.
globenewswire.com
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...
1
0
0
🤝 Hinge Bio announces potential $105M license and collaboration deal with Kyorin Pharmaceutical Co., Ltd. for bispecific antibody HB2198 in Japan for autoimmune diseases.
1
0
0
🧪 Zenas BioPharma and InnoCare Pharma announce $2B+ license agreement granting Zenas rights for three autoimmune product candidates, including obexelimab.
investors.zenasbio.com
- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of...
1
0
0
💸 @Eradivir secures $10M in private financing to advance pipeline from proprietary BAiT platform (Bispecific Antigenic immuno-Therapy).
biospace.com
1
0
0
🌱 Aerska launches with $21M in financing for antibody-oligo conjugate (AOC) platform to develop RNAi medicines.
globenewswire.com
Aerska Launches with $21 Million in Financing to Develop RNAi Medicines for Diseases of the Brain...
1
0
0
🎁 @LeydenLabs secures €30M from European Innovation Council Fund and Invest-NL to advance antibody-based nasal sprays against respiratory viruses.
leydenlabs.com
Dutch biotech Leyden Labs has raised a €30 million equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray, as well as...
0
0
0
🎁 Igyxos Biotherapeutics awarded EUR 5.7M from the French Government to accelerate development of monoclonal antibody IGX12 for infertility.
igyxos.com
1
0
0
💸 Valink Therapeutics closes $11.8M Pre-A financing round to advance bispecific ADC pipeline.
1
0
0
💸 @CartographyBio receives $67M Series B financing to advance differentiated oncology pipeline of antibody-based therapies into the clinic.
1
0
0
💸 Adcytherix raises EUR 105M Series A to advance ADC pipeline with focus on novel payloads.
adcytherix.com
October 16, 2025 • Financing led by Bpifrance with co-leads Kurma Partners, Andera Partners and Angelini Ventures, followed by other prestigious new investors, Surveyor Capital (a Citadel company)...
1
0
0
💵 Jade Biosciences announces $135M private placement to fund R&D, including antibody pipeline.
jadebiosciences.com
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on...
1
0
0
💵 @spyretx announces closing of public offering of $316M.
ir.spyre.com
WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody enginee...
1
0
0
💵 @SMMT_TX raises $500M in private placement to advance pipeline including bispecific ivonescimab.
businesswire.com
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech...
1
0
0
💸 Pinetree Therapeutics raises $47M in Series B to advance next-generation protein degraders in oncology.
pinetreetx.com
1
0
0
💸 @Hemab_Tx announces $157M Series C financing to advance antibody treatments for underserved bleeding disorders.
1
0
0
💸 @ELECTRA_Biotech announces $183M Series C financing to advance first-in-class SIRP-directed antibodies.
1
0
0
💸 TORL BioTherapeutics secures $96M Series C financing to advance antibody-drug conjugate TORL-1-23.
prnewswire.com
Secured $96M Series C Financing; Total Raised Since 2019 Founding Exceeds $450M Proceeds Fund the Clinical Development of TORL-1-23, Currently in a...
1
0
0
💸 @Tubulis_GmbH closes $401M Series C to accelerate clinical development of lead ADC candidate TUB-040 and expand pipeline.
tubulis.com
Tubulis completes €308M Series C round to advance ADC candidate TUB-40 into clinical development and broaden its oncology pipeline.
1
0
0